

COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231



Atty Dkt No. 0800-0026

COPY OF PAPERS  
ORIGINALLY FILED

TECH CENTER 1600/2900

MAY 01 2002

RECEIVED

FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 1 of 1

In the Application of OZAWA et al.

Serial No.: 09/932,451

Art Unit: ~~1632~~ 1635

Filed: August 17, 2001

Examiner: Unassigned

Title: ADENO-ASSOCIATED VIRUS-MEDIATED DELIVERY OF ANGIOGENIC FACTORS

U.S. PATENT DOCUMENTS

Exam. Init.	Ref. Desig.	Document No.	Date	Name	Class	Sub Class	Filing Date
DW	AA-2	6,162,796	December 19, 2000	Kaplitt et al.	514	54	

FOREIGN PATENT DOCUMENTS

Exam. Init.	Ref. Desig.	Document No.	Publication Date	Country or Patent Office	Class	Sub Class	Translation YES	NO
	AB-2							

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Exam. Init.	Ref. Desig.	Description
	AC-2	

Examiner: Brian A. Adams

Date Considered: 10/31/03

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

3C997 U.S. PRO  
09/932451  
08/17/01

COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 1 of 4

In the Application of OZAWA et al.

Serial No.: Unassigned

Art Unit: Unassigned 1635

Filed: Even Date Herewith

Examiner: Unassigned

Title: ADENO-ASSOCIATED VIRUS-MEDIATED DELIVERY OF ANGIOGENIC FACTORS

U.S. PATENT DOCUMENTS

Exam. Init.	Ref. Desig.	Document No.	Date	Name	Class	Sub Class	Filing Date
BW	AA-1	5,858,351	January 12, 1999	Podsakoff et al.	424	93.2	
BW	AB-1	6,211,163	April 3, 2001	Podsakoff et al.	514	44	

FOREIGN PATENT DOCUMENTS

Exam. Init.	Ref. Desig.	Document No.	Publication Date	Country or Patent Office	Class	Sub Class	Translation YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Exam. Init.	Ref. Desig.	Description
BW	AC-1	Asahara, et al., "Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer," <i>Circulation</i> <u>94</u> :3291-3302 (1996)
BW	AD-1	Banai, et al., "Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs," <i>Circulation</i> <u>89</u> :2183-2189 (1994)

Examiner: Banai et al.

Date Considered: 10/31/03

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 2 of 4

In the Application of OZAWA et al.

Serial No.: Unassigned

Art Unit: ~~Unassigned~~ 1635

Filed: Even Date Herewith

Examiner: Unassigned

Title: ADENO-ASSOCIATED VIRUS-MEDIATED DELIVERY OF ANGIOGENIC FACTORS

Exam. Init.	Ref. Desig.	Description
BV	AE-1	Baumgartner, et al., "Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia," <i>Circulation</i> <u>97</u> :1114-1123 (1998)
	AF-1	Ferrara, et al., "Molecular and biological properties of the vascular endothelial growth factor family of proteins," <i>Endocr. Rev.</i> <u>13</u> :18-32 (1992)
	AG-1	Guzman, et al., "Efficient gene transfer into myocardium by direct injection of adenovirus vectors," <i>Circ. Res.</i> <u>73</u> :1202-1207 (1993)
	AH-1	Hariawala, et al., "VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts," <i>J. Surg. Res.</i> <u>63</u> :77-82 (1996)
	AI-1	Henry, et al., "Double blind, placebo controlled trial of recombinant human vascular endothelial growth factor-the VIVA Trial," <i>J. Am. Coll. Cardiol.</i> <u>33</u> :384A (1999)
	AJ-1	Hojo, et al., "Expression of vascular endothelial growth factor in patients with acute myocardial infarction," <i>J. Am. Coll. Cardiol.</i> <u>35</u> :968-973 (2000)
	AK-1	Isner, et al., "Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb," <i>Lancet.</i> <u>348</u> :370-374 (1996)
	AL-1	Leung, et al., "Vascular endothelial growth factor is a secreted angiogenic mitogen," <i>Science</i> <u>246</u> :1306-1309 (1989)
BV	AM-1	Losordo, et al., "Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia," <i>Circulation</i> <u>98</u> :2800-2804 (1998)

Examiner: *P. J. A. Hume*

Date Considered: *10/11/02*

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 3 of 4

In the Application of OZAWA et al.

Serial No.: Unassigned

Art Unit: Unassigned 163

Filed: Even Date Herewith

Examiner: Unassigned

Title: ADENO-ASSOCIATED VIRUS-MEDIATED DELIVERY OF ANGIOGENIC FACTORS

Exam. Init.	Ref. Desig.	Description
<u>RV</u>	AN-1	Mack, <i>et al.</i> , "Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion," <i>J. Vasc. Surg.</i> <u>27</u> :699-709 (1998)
	AO-1	Mack, <i>et al.</i> , "Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart," <i>J. Thorac. Cardiovasc. Surg.</i> <u>115</u> :168-176 (1998); discussion 176-167
	AP-1	Maeda, <i>et al.</i> , "Gene transfer into vascular cells using adeno-associated virus (AAV) vectors," <i>Cardiovasc. Res.</i> <u>35</u> :514-521 (1997)
	AQ-1	Maeda, <i>et al.</i> , "Efficient gene transfer into cardiac myocytes using adeno-associated virus (AAV) vectors," <i>J. Mol. Cell Cardiol.</i> <u>30</u> :1341-1348 (1998)
	AR-1	Maeda, <i>et al.</i> , "Adeno-Associated Virus-Mediated Vascular Endothelial Growth Factor Gene Transfer in to Cardiac Myocytes," <i>J. Cardiovasc. Pharmacol.</i> <u>36</u> :438-443 (2000)
	AS-1	Magovern, <i>et al.</i> , "Direct in vivo gene transfer to canine myocardium using a replication-deficient adenovirus vector," <i>Ann. Thorac. Surg.</i> <u>62</u> :425-433 (1996)
	AT-1	Muhlhauser, <i>et al.</i> , "VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo," <i>Circ. Res.</i> <u>77</u> :1077-1086 (1995)
<u>RV</u>	AU-1	Neufeld, <i>et al.</i> , "Vascular endothelial growth factor (VEGF) and its receptors," <i>FASEB J.</i> <u>13</u> :9-22 (1999)

Examiner:

Date Considered:

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 4 of 4

In the Application of OZAWA et al.

Serial No.: Unassigned

Art Unit: ~~Unassigned~~ 1635

Filed: Even Date Herewith

Examiner: Unassigned

Title: ADENO-ASSOCIATED VIRUS-MEDIATED DELIVERY OF ANGIOGENIC FACTORS

Exam. Init.	Ref. Desig.	Description
<u>AV</u>	AV-1	Rosengart, <i>et al.</i> , "Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease," <i>Circulation</i> <u>100</u> :468-474 (1999)
	AW-1	Shibuya, <i>et al.</i> , "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family," <i>Oncogene</i> <u>5</u> :519-524 (1990)
	AX-1	Shulick, <i>et al.</i> , "In vivo gene transfer into injured carotid arteries. Optimization and evaluation of acute toxicity," <i>Circulation</i> <u>91</u> :2407-2414 (1995)
	AY-1	Springer, <i>et al.</i> , "VEGF gene delivery to muscle: potential role for vasculogenesis in adults," <i>Mol. Cell</i> <u>2</u> :549-558 (1998)
	AZ-1	Svensson, <i>et al.</i> , "Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors," <i>Circulation</i> <u>99</u> :201-205 (1999)
	BA-1	Takeshita, <i>et al.</i> , "Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model," <i>J. Clin. Invest.</i> <u>93</u> :662-670 (1994)
<u>BB</u>	BB-1	Tsurumi, <i>et al.</i> , "Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion," <i>Circulation</i> <u>94</u> :3281-3290 (1996)

Examiner: P. M. P. H.

Date Considered: 10/31/03

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.